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Abstract
Background: Influenza cohort studies, in which participants are monitored for infection over an epidemic period, are
invaluable in assessing the effectiveness of control measures such as vaccination, antiviral prophylaxis and non-
pharmaceutical interventions (NPIs). Influenza infections and illnesses can be identified through a number of approaches
with different costs and logistical requirements.
Methodology and Principal Findings: In the context of a randomized controlled trial of an NPI with a constrained budget,
we used a simulation approach to examine which approaches to measuring outcomes could provide greater statistical
power to identify an effective intervention against confirmed influenza. We found that for a short epidemic season, the
optimal design was to collect respiratory specimens at biweekly intervals, as well as following report of acute respiratory
illness (ARI), for virologic testing by reverse transcription polymerase chain reaction (RT-PCR). Collection of respiratory
specimens only from individuals reporting ARI was also an efficient design particularly for studies in settings with longer
periods of influenza activity. Collection of specimens only from individuals reporting a febrile ARI was less efficient.
Collection and testing of sera before and after influenza activity appeared to be inferior to collection of respiratory
specimens for RT-PCR confirmation of acute infections. The performance of RT-PCR was robust to uncertainty in the costs
and diagnostic performance of RT-PCR and serological tests.
Conclusions and Significance: Our results suggest that unless the sensitivity or specificity of serology can be increased RT-
PCR will remain as the preferable outcome measure in NPI studies. Routine collection of specimens for RT-PCR testing even
when study participants do not report acute respiratory illness appears to be the most cost efficient design under most
scenarios.
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Introduction
Influenza is a major cause of mortality and morbidity worldwide
[1]. Field studies of influenza have been invaluable for understand-
ing influenza epidemiology [2,3]. In a ‘healthy cohort’ study,
participants are enrolled in a defined period, usually before the start
of an influenza epidemic season, and are followed up to measure the
incidence of influenza infections and illnesses usually through one or
more entire epidemics. Many randomized controlled trials (RCTs)
studying the efficacy of influenza vaccinations [4,5,6,7,8,9,10,11],
antiviral prophylaxis [12,13,14,15,16,17,18,19], and non-pharma-
ceutical interventions [20,21,22,23,24,25] at preventing influenza
infection and illness have followed healthy cohort study designs.
There are a variety of ways to identify influenza infections in
cohorts (Table 1) [26,27,28,29]. Because acute upper respiratory
tract infections (URTIs) associated with different pathogens can
have similar clinical presentation, the sensitivity and specificity of
syndromic classifications of influenza infection, or proxy measures
such as absenteeism, tend to be poor when compared to
laboratory-based outcomes [26]. Respiratory specimens, such as
nasal swabs or aspirates, can be collected from patients with acute
URTI for virologic testing. These methods have high specificity
and high sensitivity to correctly identify acute influenza virus
infections and exclude other causes, with reverse transcription
polymerase chain reaction (RT-PCR) recently superseding viral
culture as the gold standard virologic approach [29,30]. However,
due to the relatively short duration of influenza viral shedding
during acute course of infection, respiratory specimens should be
collected within 3–5 days of illness onset [31,32,33], although
asymptomatic infections can also be identified by virologic testing
[31,32]. Because collection and testing of respiratory specimens is
costly, most cohort studies using virologic outcomes have collected
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respiratory specimens only following onset of illness in subjects
[5,6,23] although it could be feasible to arrange routine collection
of specimens at regular intervals. Consequently, if RT-PCR is to
be used as the main influenza diagnostic method in cohort studies,
considerable resources must be devoted to the timely identification
of illnesses in subjects and collection of respiratory specimens. In
contrast, serologic testing of paired sera collected before and after
epidemic periods of influenza activity can be easier to coordinate,
and rises in antibody titers during the influenza season can indicate
recent infection albeit with lower sensitivity and specificity than
RT-PCR [26] and with specific limitations for identifying
infections in recipients of influenza vaccine because of falling
antibody titers after vaccination [30,34].
While timely collection of respiratory specimens allows sensitive
identification of influenza infections, many acute URTIs are not
caused by influenza virus infections [35,36,37]. Therefore, when
planning to collect specimens for RT-PCR testing following report
of an acute URTI, it is important to consider the expected
incidence rates of URTIs with various presentations in the
fieldwork budget. Within a constrained budget, the costs of
collection and testing of specimens has to be offset against the
number of participants enrolled in the study, but this can be
problematic given that the incidence of influenza and other
respiratory diseases varies from year to year. If the incidence of
influenza and other respiratory diseases is lower than expected and
fewer specimens are collected, some funds for testing may remain
unspent, while if activity is higher, funding may be insufficient to
collect and test specimens from all illnesses.
It is unclear which laboratory approach – serology or RT-PCR
– is the most cost effective and efficient for use in intervention
studies based on healthy cohort designs. Selecting the best design
to maximize study power given fixed available resources is part of
Good Clinical Practice and suboptimal designs could waste
valuable resources or inconvenience patients unnecessarily. Our
objective here is to identify cohort study designs which can
maximize statistical power to detect a difference between an
intervention and a control arm in preventing influenza infections.
Methods
We simulated a comparative study for a ‘healthy cohort’ of
participants that are not infected with influenza at recruitment.
We assume that participants in the cohort are individually
randomized in equal proportions between an intervention arm
and a control arm (or between two intervention arms), as balanced
studies tend to have greater statistical power than unbalanced
studies. We proceed under the assumption that the intervention
being considered is an NPI, such as wearing face masks or shields,
or increasing their hand hygiene behaviors. We assume that all
participants are recruited independently and are not members of
the same households, schools, or otherwise clustered.
A range of syndromic definitions have been used as proxy
outcomes in influenza studies, including definitions aiming at
greater sensitivity such as ‘‘acute respiratory illness’’ (ARI) defined
as any two of a range of respiratory and systemic symptoms (e.g.
fever $37.8uC, cough, headache, sore throat, or myalgia) as well
as definitions aiming at greater specificity by restricting to febrile
Table 1. Approaches to identify influenza infection and illness or their correlates in community-based studies.
Category Approach Advantages Disadvantages
Serologic confirmation Paired sera taken before and after the influenza
season with four-fold rise in antibody titers
typically used as evidence of infection.
N Generally high sensitivity and
specificity to identify infections
N Collection of sera is invasive
N Requires laboratory expertise
N Not all infections are associated with rises in
antibody titers (i.e. imperfect sensitivity)
N Cross-reactive antibody responses can be
associated with a lack of specificity
Virologic confirmation RT-PCR analysis of throat or nose swabs N Gold standard for diagnosis of
influenza infection
N Requires a respiratory specimen collected within
3–5 days of symptom onset [32,33]
Viral culture N Virus is recoverable for further
analysis [48]
N Expensive
N Time intensive [48]
Rapid antigen test N Fast—gives results within hours N Lower sensitivity than viral culture or RT-PCR
[49,50,51]
Clinical outcomes Hospitalisations associated with confirmed
influenza
N Confirmed infection of clinical
importance
N Rare event so is a low-powered endpoint
Hospitalisations associated with influenza-like
illness
N Outcome of clinical importance N Rare event so is a low-powered endpoint
Outpatient consultations associated with
confirmed influenza
N Confirmed infection of clinical
importance
N Misses less serious influenza infections [20]
Proxy outcomes Absenteeism Easy to collect data especially in
school or workplace [52]
Not influenza specific
Based on reported
signs and symptoms
Acute respiratory illness (ARI), an acute upper
respiratory tract infection which is not
necessarily associated with febrile illness; one
common definition is at least two of body
temperature $37.8uC, cough, headache, sore
throat, phlegm or myalgia [26,27]
N Does not require clinical
specimens or laboratory tests
N Higher sensitivity than FARI
N Lower specificity than FARI
N Lower sensitivity and specificity than laboratory
confirmed outcomes
A febrile ARI (FARI), an acute upper respiratory
tract infection, one common definition is body
temperature $37.8uC plus cough or sore throat
[26,27]
N Does not require clinical
specimens or laboratory tests
N Higher specificity than ARI
N Lower sensitivity and specificity than laboratory
confirmed outcomes
doi:10.1371/journal.pone.0035166.t001
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ARI (FARI) for example the CDC surveillance definition of
‘‘influenza-like illness’’ as fever $37.8uC plus cough or sore throat
[20,26,27,38].
We consider seven alternative approaches to identification of
influenza infections in the comparative study:
1. Collection and testing by RT-PCR of respiratory specimens
from participants reporting FARI.
2. Collection and testing by RT-PCR of respiratory specimens
from participants reporting ARI.
3. Collection and testing by RT-PCR of respiratory specimens
collected from all participants at biweekly intervals regardless
of illness, as well as from any participants reporting ARI.
4. Collection of paired serum from all participants plus collection
and testing by RT-PCR of respiratory specimens from
participants reporting FARI.
5. Collection of paired serum from all participants plus collection
and testing by RT-PCR of respiratory specimens from
participants reporting ARI.
6. Collection of paired serum from all participants plus collection
and testing by RT-PCR of respiratory specimens collected
from all participants at biweekly intervals regardless of illness,
as well as from any participants reporting ARI.
7. Collection of paired serum from all participants but no
collection of respiratory specimens.
In these approaches, ARI and FARI trigger refers to collection
of respiratory specimens within 1–3 days of onset of illness only if
and when ARI or FARI are reported by a study participant.
Because our interest is in studies that can demonstrate effectiveness
of interventions against influenza specifically, we did not consider
ARI or FARI as primary outcomes in our analysis and therefore of
primary relevance to the present optimal design considerations,
although they might be included as secondary outcomes. For
analysis of paired sera a 4-fold or greater rise in antibody titers on
hemagglutination inhibition (HI) assays is used to indicate
infection [26]. We did not consider proxy outcomes such as
absenteeism, or clinical outcomes such as hospital admissions or
outpatient visits because they were believed to have low power as
study endpoints [20,26].
Table 1 shows the parameter values used in our simulations. We
assumed that the intervention could reduce the risk of influenza
virus infections by 30%, with a consequent reduction in the rates
of ARI and FARI episodes associated with influenza. Our
simulations also allowed for an effect of the NPI on the rates of
ARI and FARI episodes not associated with influenza
[39,40,41,42]. For simplicity we assume that the risk of ARI and
FARI associated with non-influenza infections is independent of
the transmission dynamics of and infection with influenza virus
and vice versa. For each study design variant, we used a Monte
Carlo approach to randomly simulate a set of 2500 datasets. For
each dataset we used chi-squared tests of the difference between
arms in the proportion of laboratory confirmed infections. The
proportion of datasets in which the null-hypothesis of no difference
was rejected at the 0.05 significance level was defined as the
statistical power [33,43]. Further technical details are provided in
Text S1.
For each study budget, we calculated the number of participants
per arm that can be recruited given the chosen diagnostic method
and consequent costs of follow-up, as well as the anticipated ‘base
case’ level of ARI and FARI incidence. We investigated the effect
on study power to variability in the activity of influenza and other
respiratory viruses during the study as a key sensitivity analysis.
This was done because in the case of respiratory specimen
collection triggered by ARI or FARI, the number of specimens
collected could exceed the allotted budget if the activity of
influenza and other non-influenza respiratory viruses was higher
than anticipated. If that occurred in our simulation, only the
number of specimens allowed by the study budget was tested.
Simulations were performed assuming three different scenarios. In
the first scenario (I) we assume that the cumulative incidence of
ARI and FARI not associated with influenza in the control arm
are 0.40 and 0.10 respectively and that these are correctly
estimated in advance of the study. In the scenarios (II) and (III) the
cumulative incidence of non-influenza ARI and FARI are again
0.40 or 0.10 but for purposes of study planning these are believed
incorrectly to be 0.20 and 0.06 or 0.60 and 0.14 respectively.
Scenarios II and III are used to illustrate how underestimation or
over-estimation of ARI and FARI attack rates will reduce the
power of detection methods relying on ARI or FARI report or
trigger. Power, sample size, and cumulative incidence of infection
in the control arm (i.e. proportion of control arm participants
identified as having influenza) were plotted as a function of field
budget for these three scenarios.
Sensitivity Analyses
Due to uncertainties in model parameters, we performed several
sensitivity analyses to examine how sensitive power estimates were
to variations in model parameters (Table 2). Specifically, we
examined the sensitivity of power estimates to differing influenza
cumulative incidences, the effect of the NPI intervention on the
rate of non-influenza ARI and FARI, the cost of RT-PCR testing,
the cost of serological testing, the sensitivity of RT-PCR testing
and the sensitivity and specificity of serology. In another sensitivity
analysis, we assumed a longer, six-month influenza season with
lower incidence rates but the same cumulative incidence of
infection across the study as the base case.
Results
Model results for the base case parameters are shown in Figure 1
for Scenarios I-III. A summary of the results is given in Table 3. In
all scenarios, biweekly RT-PCR plus trigger yielded greater power
than other study designs. In Scenario I in which expected rates of
ARI and FARI noise matched actual rates, biweekly RT-PCR plus
ARI trigger followed by RT-PCR upon ARI trigger were the most
powerful study designs. The higher power of biweekly RT-PCR
plus ARI trigger was robust to underestimation or overestimation
of ARI and FARI rates (Scenarios II and III). Study design
variants relying on RT-PCR generally had higher power than
serological testing despite having much lower cumulative inci-
dence of confirmed influenza (Figure 1) although in all scenarios
RT-PCR upon FARI trigger performed worse or equal in terms of
statistical power to serology or the combination of serology and
RT-PCR. Cumulative incidence of confirmed influenza in the
control arms were highest for study designs that involved serology,
and lowest for the study design based on collection of specimens
upon FARI trigger.
Sensitivity Analyses
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, and
Figure S6 examine the sensitivity of observed statistical power to
cumulative incidence of influenza infection, to the effectiveness of
the intervention to reduce non-influenza ARI and FARI, the cost
of RT-PCR, the cost of serology, the sensitivity of RT-PCR, and
the sensitivity and specificity of serology respectively. Figure S7
shows the effect of increasing the follow-up time from 2 months to
Design of Influenza Cohort Studies
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6 months without changing the overall cumulative incidence of
infection. In these illustrations, biweekly RT-PCR plus ARI trigger
yielded the greatest power except for two cases: serology was
similar to biweekly RT-PCR plus ARI trigger when the sensitivity
and specificity of serological testing were increased, and RT-PCR
upon ARI trigger performed the best for a longer six-month
follow-up period. When the cost of serological testing was reduced,
the cost of RT-PCR was increased or the sensitivity of RT-PCR
was reduced, designs relying on RT-PCR still appeared to
outperform serology indicating that RT-PCR is generally more
efficient unless the sensitivity and specificity of serology can be
increased.
Discussion
We found that study design variants based on collection of
respiratory specimens for RT-PCR testing almost always per-
formed better than study design variants based on serology. Unless
the duration of influenza activity was greater than two months,
biweekly RT-PCR plus RT-PCR upon ARI trigger was not
dominated by any other method. It should be noted that study
design variants relying on serological testing had lower statistical
power than RT-PCR despite being able to identify a greater
proportion of influenza infections. This is consistent with several
studies [5,6] which report higher cumulative incidence of influenza
across a season based on serology than RT-PCR and is due to a
number of factors: high specificity of RT-PCR, comparatively
lower specificity of serology, the greater ability of serology to
identify asymptomatic and subclinical infections, and underre-
porting of symptoms by participants. It is possible for the number
of triggered RT-PCR tests required to exceed the number
budgeted if more ARI or FARI cases are reported than expected.
When this occurred in our simulations, we simulated the cessation
of collection or analysis of specimens after the allotted field budget
was exhausted. However, if an investigator were able to procure
additional funds to collect and analyze the additional specimens
required by circumstance this would further increase the power of
a design relying on RT-PCR.
These results illustrate that careful planning is necessary when
considering the design of cohort studies for influenza. We have
purposely intended the present analysis to focus on the design of
NPI studies. Our results might be applicable to studies of either
vaccine or antiviral prophylaxis with some caveats. In vaccine
trials, receipt of the vaccine usually results in higher initial
antibody levels following vaccination, making interpretation of
paired serology difficult [30,44]. However our observation that
routine collection of respiratory specimens was more efficient than
relying on illness trigger may still hold. Regarding antiviral
prophylaxis, those receiving treatment could potentially have
similar rates of infection as controls but have lower levels and
duration of viral shedding and reduced severity of symptoms thus
reducing the sensitivity of RT-PCR and clinical definitions [45].
While our results may serve as a broad guideline for
investigators planning a cohort study, some limitations exist which
may limit their use in practice. First, our models are somewhat
sensitive to estimates of serology and RT-PCR costs and their
sensitivity and specificity. It is likely that these estimates, especially
of costs, would vary geographically. Therefore, we have presented
a range of sensitivity analyses varying important model parame-
ters. Second, it is important to note that our results apply only to
naturally acquired influenza as opposed to volunteer challenge
studies where participants are experimentally exposed to influenza
virus [31,46]. Challenge studies could be more resource efficient
than cohort studies in assessing the potential benefits of
interventions at preventing infection, although the results may
not be generalizable to the use or effectiveness of interventions in
natural settings [47]. Third, our results are also specifically based
on viral shedding data of influenza A. Influenza B has slightly
Table 2. Parameter values and ranges of the input values in sensitivity analysis.
Parameter Value Sensitivity analysis Source
Length of the study 2 months assumed
Primary cumulative incidence (control) 0.15 0.1, 0.3 assumed
Treatment efficacy 0.30 assumed
Package cost of enrollment of a subject US$500 (B. J. Cowling, personal
communication)
Package cost of collection of a respiratory specimen
from a subject and testing by RT-PCR
US$65 US$35, US$130 (B. J. Cowling, personal
communication)
Package cost of collection of paired serology from a
subject and testing by hemagglutination inhibition
US$130 US$65, US$280 (B. J. Cowling, personal
communication)
Serology sensitivity 0.84 0.76, 0.92 [29,53]
Serology specificity 0.88 0.80, 0.96 [29]
RT-PCR sensitivity Various depending
on timing
Area under the curve decreased by
20% and increased by 10%
[33]
RT-PCR specificity 0.99 [33]
ARI sensitivity for case-ascertained studies 0.68 [33]
FARI sensitivity for case-ascertained studies 0.40 [33]
Reporting rate for cohort studies as compared to
case-ascertained studies
0.70 assumed
Control Non-influenza ARI rate 0.40 [6]
Control Non-influenza FARI rate 0.10 [6]
Reduction in rate of non-influenza ARI and FARI 0.15 0, 0.30 assumed
doi:10.1371/journal.pone.0035166.t002
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different epidemiologic characteristics including possibly a longer
duration of infectiousness [31,32]. Finally, we did not consider
cluster studies such as school or household-based studies, where
optimal design may differ due to correlation in the risk of infection
and potential differences in logistics and resources required for
fieldwork.
While our study identified RT-PCR as an optimal design by
comparing statistical power among different designs as a function
of budget, it should be noted that other laboratory testing methods
can still be optimal for other clinical or public health objectives.
When influenza diagnosis is followed by treatment or public health
intervention of potential contacts, testing methods are subject to
other considerations. In such an instance, the objectives may be to
improve clinical outcome by early treatment or to prevent
secondary transmission and thus speed of diagnosis is of critical
importance. While our results may not be applicable to this type of
study, similar simulation approaches could be used to assess
optimal design for other specific objectives under consideration.
In conclusion, large sample sizes are often needed in influenza
intervention studies because of the low incidence of influenza and
Figure 1. Comparison of alternative study designs. In the plot, the three rows indicate: (A) power, (B) total sample size per arm, and (C)
estimated cumulative incidence of influenza in the control arm. Scenario I assumes the unbiased control non-influenza attack ARI and FARI rates are
0.4 and 0.1 respectively which exactly correspond to estimates made in advance of the study. Scenario II assumes the unbiased control non-influenza
attack ARI and FARI rates are 0.4 and 0.1 but are underestimated at 0.2 and 0.06 when planning the study. Scenario III assumes the unbiased control
non-influenza attack ARI and FARI rates are 0.4 and 0.1 and but are overestimated at 0.6 and 0.14 when planning the study. Control arm cumulative
incidence proportion refers to the expected proportion of participants identified as having influenza infection among the control arm. ‘‘Combined’’
refers to paired serology analyzed by HAI plus RT-PCR upon ARI trigger. Black lines are used to denote design variants using RT-PCR confirmation.
Grey lines are used to denote design variants using serologic confirmation or serologic plus RT-PCR confirmation.
doi:10.1371/journal.pone.0035166.g001
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the moderate effects of many interventions. Our results show that
a design using biweekly RT-PCR plus ARI trigger, a cumulative
incidence of influenza infection of 15% and moderate intervention
efficacy of 30%, approximately 1,400 participants (700 to 1800
depending on cumulative incidence of influenza infection) per arm
would need to be recruited to achieve 80% power. Further
research should continue to improve the accuracy of estimates of
the sensitivity and specificity of laboratory methods which would
help to improve study power, particularly when comparing
serologic and virologic approaches to ascertainment of influenza
infections. New laboratory methods may emerge which the
accuracy or cost of current techniques and thus would allow for
more efficient designs.
Supporting Information
Text S1 Supplemental Appendix with additional technical
details.
(DOC)
Figure S1 Power of competing influenza diagnostic
methods for Scenarios I–III. Sensitivity analysis (a) is when
the control arm cumulative incidence is reduced to 0.1 and
sensitivity analysis (b) is when the control arm cumulative
incidence is reduced to 0.3.
(TIF)
Figure S2 Power of competing influenza diagnostic
methods for Scenarios I–III. Sensitivity analysis (a) is when
the NPI intervention has no effect on non-influenza ARI and
FARI rate but we plan for a 15% reduction and sensitivity analysis
(b) is when the NPI intervention reduces the non-influenza ARI
and FARI rate by 30% but we plan for a 15% reduction.
(TIF)
Figure S3 Power of competing influenza diagnostic
methods for Scenarios I–III. Sensitivity analysis (a) is when
the cost of RT-PCR testing is small (US$35) and sensitivity
analysis (b) when the cost is large (US$130).
(TIF)
Figure S4 Power of competing influenza diagnostic
methods for Scenarios I–III. Sensitivity analysis (a) is when
the cost of serology is small (US$130) and sensitivity analysis (b) is
when the cost of serology is large (US$195).
(TIF)
Figure S5 Power of competing influenza diagnostic
methods for Scenarios I–III. Sensitivity analysis (a) is when
the sensitivity of RT-PCR is reduced by 20% (by AUC) and
sensitivity analysis (b) is when the sensitivity of RT-PCR increased
by 10% (by AUC).
(TIF)
Figure S6 Power of competing influenza diagnostic
methods for Scenarios I–III. Sensitivity analysis (a) is when
the sensitivity and specificity of serology is reduced to 0.76 and
0.80 respectively and sensitivity analysis (b) is when the sensitivity
and specificity of serology is increased to 0.92 and 0.96
respectively.
(TIF)
Figure S7 Power of competing influenza diagnostic
methods for Scenarios I–III. Sensitivity analysis is for a six
month follow-up rather than two-months.
(TIF)
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